Literature DB >> 21882020

Surgical impact on gastric cancer with locoregional invasion.

Kuan-Kai Lai1, Wen-Liang Fang, Chew-Wun Wu, Kuo-Hung Huang, Jen-Hao Chen, Su-Shun Lo, Anna Fen-Yau Li.   

Abstract

BACKGROUND: The benefit of resection of gastric cancer with locoregional invasion is still under debate. This study aimed to investigate the impact of surgery on patients with gastric cancer with locoregional invasion.
METHODS: From January 1988 to December 2009, a total of 2,678 patients with gastric cancer underwent surgery at the Department of Surgery, Taipei Veterans General Hospital. Among these patients, 569 and 295 were diagnosed as T4a (serosa invasion without penetration of visceral peritoneum) and T4b (serosa exposure with invasion of adjacent structure), respectively. Invasion type and prognosis were analyzed in patients with gastric cancer who had either curative or palliative resection.
RESULTS: Our results showed that patients with T4a gastric cancer had a better 5-year overall survival than patients with T4b (22.5% vs. 11.5%, P < 0.001). Patients with T4b who had curative resection had a better 5-year overall survival than those with T4b who had palliative resection (13.8% vs. 7.3%, P = 0.001). The prognosis of patients with gastric cancer with pancreas invasion was worse than those with mesocolon invasion, as no patients with pancreas invasion survived more than 5 years. Univariate and multivariate analyses showed that tumor size (P = 0.019), Bormann classification (P < 0.001), stromal reaction (P = 0.001), and nodal involvement (P < 0.001) were independent predictors for overall survival in patients with T4b gastric cancer.
CONCLUSION: Resection of T4b gastric cancer could be performed with curative intent. Patients with gastric cancer with pancreas invasion had a poorer prognosis than those with mesocolon invasion.

Entities:  

Mesh:

Year:  2011        PMID: 21882020     DOI: 10.1007/s00268-011-1246-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

1.  Nodal dissection for patients with gastric cancer: a randomised controlled trial.

Authors:  Chew-Wun Wu; Chao A Hsiung; Su-Shun Lo; Mao-Chin Hsieh; Jen-Hao Chen; Anna Fen-Yau Li; Wing-Yiu Lui; Jacqueline Whang-Peng
Journal:  Lancet Oncol       Date:  2006-04       Impact factor: 41.316

2.  Prognosis of gastric carcinoma invading the mesocolon.

Authors:  Seong Yeob Ryu; Jae Kyoon Joo; Young Kyu Park; Young Jin Kim; Shin Kon Kim; Jae Hyuk Lee; Dong Yi Kim
Journal:  Asian J Surg       Date:  2008-10       Impact factor: 2.767

3.  Prognosis and surgical treatment of gastric cancer invading the pancreas.

Authors:  Y Maehara; H Oiwa; S Tomisaki; Y Sakaguchi; A Watanabe; H Anai; K Sugimachi
Journal:  Oncology       Date:  2000-06       Impact factor: 2.935

4.  Extended local resection for advanced gastric cancer: increased survival versus increased morbidity.

Authors:  Robert C G Martin; David P Jaques; Murray F Brennan; Martin Karpeh
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

5.  Should direct mesocolon invasion be included in T4 for the staging of gastric cancer?

Authors:  Jung Hoon Park; Woo Jin Hyung; Seung Ho Choi; Sung Hoon Noh
Journal:  J Surg Oncol       Date:  2010-03-01       Impact factor: 3.454

6.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

7.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

8.  Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.

Authors:  A F C Okines; A R Norman; P McCloud; Y-K Kang; D Cunningham
Journal:  Ann Oncol       Date:  2009-05-27       Impact factor: 32.976

9.  Aggressive surgical treatment for T4 gastric cancer.

Authors:  Akihiko Kobayashi; Toshio Nakagohri; Masaru Konishi; Kazuto Inoue; Shinichirou Takahashi; Masaaki Itou; Masanori Sugitou; Masato Ono; Norio Saito; Taira Kinoshita
Journal:  J Gastrointest Surg       Date:  2004 May-Jun       Impact factor: 3.452

10.  Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM.

Authors:  Ji Yeong An; Tae Kyung Ha; Jae Hyung Noh; Tae Sung Sohn; Sung Kim
Journal:  Arch Surg       Date:  2009-01
View more
  3 in total

1.  Extended Gastrectomy for T4b Gastric Adenocarcinoma: Single-Surgeon Experience.

Authors:  Mushegh А Sahakyan; Artak Gabrielyan; Hmayak Petrosyan; Shushan Yesayan; Sevak S Shahbazyan; Arthur M Sahakyan
Journal:  J Gastrointest Cancer       Date:  2020-03

2.  Short-term safety and Long-term efficacy of multivisceral resection in pT4b gastric cancer patients without distant metastasis: a 20-year experience in China National Cancer Center.

Authors:  Xiaojie Zhang; Wanqing Wang; Lulu Zhao; Penghui Niu; Chunguang Guo; Dongbing Zhao; Yingtai Chen
Journal:  J Cancer       Date:  2022-08-15       Impact factor: 4.478

3.  Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis.

Authors:  Joseph Cowling; Bethany Gorman; Afrah Riaz; James R Bundred; Sivesh K Kamarajah; Richard P T Evans; Pritam Singh; Ewen A Griffiths
Journal:  J Gastrointest Cancer       Date:  2020-09-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.